Oruka Therapeutics
ORKA
15 hedge funds and large institutions have $1.15M invested in Oruka Therapeutics in 2014 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 2 increasing their positions, 5 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 15 → 15 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
0.37% less ownership
Funds ownership: 4.75% → 4.38% (-0.37%)
60% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 5
75% less capital inflows, than outflows
Capital inflows: $33.4K | Capital outflows: $132K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Ameriprise
Minneapolis,
Minnesota
|
+$14.6K |
| 2 |
Haberer Registered Investment Advisor
Cincinnati,
Ohio
|
+$6.26K |
| 3 |
Shepherd Kaplan Krochuk
Boston,
Massachusetts
|
+$6.26K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$4.18K |
| 5 |
Tower Research Capital (TRC)
New York
|
+$2.09K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$66.8K |
| 2 |
Virtu KCG Holdings
New York
|
-$33.4K |
| 3 |
BlackRock Advisors
Wilmington,
Delaware
|
-$15K |
| 4 |
Goldman Sachs
New York
|
-$4.18K |
| 5 |
UBS
Zurich,
Switzerland
|
-$4.18K |
ORKA Hedge Fund Activity: Q3 2014 in Review
15 of the 3,455 institutional investors tracked by Wall St. Rank reported a position in Oruka Therapeutics (ORKA) for Q3 2014, worth a combined $1.15M — down 21% from $1.46M a quarter earlier.
Fund positioning in ORKA was balanced in Q3 2014: 3 funds opened new positions, 3 closed out, 2 added to existing stakes and 5 trimmed.
The largest buyer was Ameriprise, opening a new position worth an estimated $14.6K. The largest seller was Bank of America, cutting an estimated $66.8K.
- 15 institutional investors held Oruka Therapeutics (ORKA) as of Q3 2014, unchanged from Q2 2014.
- Funds reported $1.15M of Oruka Therapeutics stock for Q3 2014, down 21% quarter-over-quarter.
- 3 funds opened new Oruka Therapeutics positions in Q3 2014 and 3 closed out, a net change of 0 holders.
- The largest Oruka Therapeutics buyer in Q3 2014 was Ameriprise, an estimated $14.6K added.
- The largest Oruka Therapeutics seller in Q3 2014 was Bank of America, an estimated $66.8K sold.
Based on aggregated 13F filings for Q3 2014.